Floatz logo

Methylphenidate

Schizophrenia Schizoaffective

The Royal Ottawa Mental Health CentreSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

30 Active assets in the Schizophrenia Schizoaffective cohort.

Asset / SponsorPhaseRating
Paliperidone Palmitate 3-Month Formulation
Luye Pharma Group Ltd.
Phase 4BBB
Olanzapine
The Royal Ottawa Mental Health Centre
Phase 4BBB
Seroquel®
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 4BBB
Raloxifene
Iris Sommer
Phase 4BBB
Lurasidone
University of Texas Southwestern Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Methylphenidate is also rated in:

attention deficit-hyperactivity disorderDormant
BBB
Indicative ·
76 / 100
View asset →
ApathyDormant
BBB
Indicative ·
72 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →